Fol. Biol. 2013, 59, 15-25
https://doi.org/10.14712/fb2013059010015
Proteinuria and Hypertension in Patients Treated with Inhibitors of the VEGF Signalling Pathway – Incidence, Mechanisms and Management
References
1. , A., Kelly, D. J., Advani, S. L., Cox, A. J., Thai, K., Zhang, Y., White, K. E., Gow, R. M., Marshall, S. M., Steer, B. M., Marsden, P. A., Rakoczy, P. E., Gilbert, R. E. (2007) Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc. Natl. Acad. Sci. USA 104, 14448-14453.
<https://doi.org/10.1073/pnas.0703577104>
2. , C., Veron, D., Aggarwal, P. K., Holzman, L., Tufro, A. (2011) Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J. Biol. Chem. 18, 39933-39944.
<https://doi.org/10.1074/jbc.M111.241620>
3. , G., Patey, N., Cazajous, G., Robert, C., Goujon, J. M., Fakhouri, F., Bruneval, P., Noel, L. H., Knebelmann, B. (2009) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol. Dial. Transplant. 24, 682-685.
<https://doi.org/10.1093/ndt/gfn657>
4. , O., Picazo, M. L, Zamora, P., Romero, S., Martinez-Ara, J., Selgas, R. (2010) Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol. Dial. Transplant. 25, 1001-1003.
<https://doi.org/10.1093/ndt/gfp666>
5. , K., Li, J., Karumanchi, S. A., Wang, E., Rondeau, E., Mukhopadhyay, D. (2004) Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/ VEGF-A) expression in podocytes. Kidney Int. 66, 1471-1478.
<https://doi.org/10.1111/j.1523-1755.2004.00910.x>
6. , M., Altundag, K. (2006) Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann. Pharmacother. 40, 2278-2279.
<https://doi.org/10.1345/aph.1H244>
7. , L. Y., Maes, H., Sweldens, C. (2007) Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann. Oncol. 18, 1121-1122.
<https://doi.org/10.1093/annonc/mdm205>
8. , V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H. P., Kikkawa, Y., Miner, J. H., Quaggin, S. E. (2003) Glomerular specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707-716.
<https://doi.org/10.1172/JCI17423>
9. , V., Quaggin, S. E. (2004) The role of VEGF-A in glomerular development and function. Curr. Opin. Nephrol. Hypertens. 13, 9-15.
<https://doi.org/10.1097/00041552-200401000-00002>
10. , V., Baelde, H. J., Quaggin, S. E. (2007) Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol. 106, 32-37.
<https://doi.org/10.1159/000101798>
11. , V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., Gerber, H. P., Ferrara, N., Barisoni, L., Alpers, C. E., Quaggin, S. E. (2008) VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129-1136.
<https://doi.org/10.1056/NEJMoa0707330>
12. , B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., Rolland, F., Demkow, T., Hutson, T. E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R., Bukowski, R. M., TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell cancer. N. Engl. J. Med., 356, 125-134.
<https://doi.org/10.1056/NEJMoa060655>
13. , N., Gerber, H. P., LeCouter, J. (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
<https://doi.org/10.1038/nm0603-669>
14. , R. R., Hole, R., Anderson, K., Satchell, S. C., Coward, R. J., Mathieson, P. W., Gillatt, D. A., Saleem, M. A., Bates, D. O., Harper, S. J. (2003) Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am. J. Physiol. 284, F1263-F1273.
15. , R. R., Saleem, M. A., Mathieson, P. W., Bates, D. O., Harper, S. J. (2005) Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am. J. Physiol. 288, F48-F57.
16. , M. S., Cunningham, D. (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69, S25-S33.
<https://doi.org/10.1159/000088481>
17. , F., Villegas, G., Teichman, J., Mundel, P., Tufro, A. (2006) Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am. J. Physiol. Renal Physiol. 291, F422-428.
<https://doi.org/10.1152/ajprenal.00448.2005>
18. , F., Kuru, O, Sentürk, U. K. (2003) Effect of nitric oxide on exercise-induced proteinuria in rats. J. Appl. Physiol. 95, 1867-1872.
<https://doi.org/10.1152/japplphysiol.00599.2003>
19. , S., Parsa, V., Heilbrun, L. K., Smith, D. W., Dickow, B., Heath, E., Vaishampayan, U. (2011) Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 22, 794-800.
<https://doi.org/10.1097/CAD.0b013e328346af0d>
20. , Z., Lesavre, P., Nejjari, M., Halbwachs-Mecarelli, L., Droz, D., Noel, L. H. (2000) Distribution of αVβ3, αVβ5 integrins and the integrin associated protein-IAP (CD47) in human glomerular diseases. Cell Adhes. Commun. 7, 441-451.
<https://doi.org/10.3109/15419060009040302>
21. , K. M., McHugh, K. P., Tsakiris, D. A., Rayburn, H., Crowley, D., Ullman-Culleré, M., Ross, F. P., Coller, B. S., Teitelbaum, S., Hynes, R. O. (1999) β-Integrin -deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229-238.
<https://doi.org/10.1172/JCI5487>
22. , J. D., Meininger, C. J., Ziche, M., Granger, H. J. (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274, H1054-H1058.
23. , H. I., Fehrenbacher, L., Hainsworth, J. D., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., Kabbinavar, F. (2005) Bevacizumab in combination with fluorouracil and leucovorin: active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23, 3502-3508.
<https://doi.org/10.1200/JCO.2005.10.017>
24. , H., Rixe, O., Billemont, B., Baumelou, A., Deray, G. (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am. J. Kidney Dis. 50, 203-218.
<https://doi.org/10.1053/j.ajkd.2007.04.025>
25. , H., Etienne-Grimaldi, M. C., Renée, N., Vignot, S., Milano, G. (2009a) Pharmacokinetics of sunitinib in hemodialysis. Ann. Oncol. 20, 190-192.
<https://doi.org/10.1093/annonc/mdn626>
26. , H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., Spano, J. P. (2009b) Management of hypertension in angiogenesis inhibitor-treated patients. Ann. Oncol. 20, 807-815.
<https://doi.org/10.1093/annonc/mdn713>
27. , H., Massard, C., Spano, J. P., Goldwasser, F., Khayat, D., Soria, J. C. (2010) VEGF signalling inhibitioninduced proteinuria: mechanisms, significance and management. Eur. J. Cancer 46, 439-448.
<https://doi.org/10.1016/j.ejca.2009.11.001>
28. , H., Sene, D., Hadoux, J., Gharbi, C., Bourry, E., Massard, C., Soria, J. C. (2011) Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment? Ann. Oncol. 22, 487-490.
<https://doi.org/10.1093/annonc/mdq743>
29. , D., Hutson, T. E., Cowey, C. L., Pickering, L. M., Larkin, J. M., Gore, M. E., Van Hemelrijck, M., McDermott, D. F., Powles, T., Chowdhury, P., Karapetis, C., Harper, P. G., Choueiri, T. K., Chowdruhy, S. (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int. 108, 1279-1283.
<https://doi.org/10.1111/j.1464-410X.2010.09990.x>
30. , T., Tam, B. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O ́Brien, S. M., Davis, R. B., Gowen, L. C., Anderson, K. D., Thurston, G., Joho, S., Springer, M. L., Kuo, C. J., McDonald, D. M. (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult vasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560-H576.
<https://doi.org/10.1152/ajpheart.00133.2005>
31. , Y. S., Park, Y. G., Kim, B. K., Han, S. Y., Jee, Y. H., Han, K. H., Lee, M. H., Song, H. K., Cha, D. R., Kang, S. W., Han, D. S. (2006) Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J. Mol. Endocrinol. 36, 377-388.
<https://doi.org/10.1677/jme.1.02033>
32. , M. H., van Esch, J. H., Sleijfer, S., Danser, A. H., van den Meiracker, A. H. (2009) Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J. Hypertens. 27, 2297-2309.
<https://doi.org/10.1097/HJH.0b013e3283309b59>
33. , M. H., Smedts, F. M., Horn, T., van Esch, J. H., Sleijfer, S., Leijten, F., Wesseling, S., Strevens, H., Danser, A. H., van den Meiracker, A. H. (2011) The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 58, 295-302.
<https://doi.org/10.1161/HYPERTENSIONAHA.111.173559>
34. , M. H., de Beer, V. J., Zhou, Z., Danser, A. H., Sleijfer, S., Duncker, D. J., van den Meiracker, A. H., Merkus, D. (2012) Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 59, 151-157.
<https://doi.org/10.1161/HYPERTENSIONAHA.111.182220>
35. , T., Kondo, T., Kimata, N., Murakami, J., Ishimori, I., Nakazawa, H., Hashimoto, Y., Kobayashi, H., Iizuka, J., Takagi, T., Yoshida, K., Tanabe, K. (2011) Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn. J. Clinc. Oncol. 41, 647-655.
<https://doi.org/10.1093/jjco/hyr015>
36. , G., Golshayan, A., Elson, P., Wood, L., Garcia, J., Bukowski, R., Rini, B. (2010) Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann. Oncol. 21, 1618-1622.
<https://doi.org/10.1093/annonc/mdp603>
37. , R., Toh, M., Garrett, M., La Fargue, J., Ni, G., Marbury, T. C., Swan, S. K., Lunde, N. M., Bello, C. L. (2010) Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J. Clin. Pharmacol. 50, 472-481.
<https://doi.org/10.1177/0091270009347868>
38. , K., Osuga, Y., Yoshino, O., Hirota, Y., Ruimeng, X., Hirata, T., Takeda, S., Yano, T., Tsutsumi, O., Taketani, Y. (2003) Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88, 2348-2351.
<https://doi.org/10.1210/jc.2002-021942>
39. , C., Bjarnason, G., Burnett, P., Creel, P., Davis, M., Dawson, N., Feldman, D., George, S., Hershman, J., Lechner, T., Potter, A., Raymond, E., Treister, N., Wood, L., Wu, S., Bukowski, R. (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 16, 543-553.
<https://doi.org/10.1634/theoncologist.2010-0263>
40. , C. H., White, K. E., Dei Cas, A., Hayward, A., Webster, Z., Bilous, R., Marshall, S., Viberti, G., Gnudi, L. (2008) Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 57, 2833-2844.
<https://doi.org/10.2337/db08-0647>
41. , S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J. (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703.
<https://doi.org/10.1016/j.cell.2007.06.054>
42. , D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
<https://doi.org/10.1126/science.2479986>
43. , R. J.,Maynard, S. E., Qian, C., Kim, L. H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., Sibai, B. M., Sukhatme, V. P., Karumanchi, S. A. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683.
<https://doi.org/10.1056/NEJMoa031884>
44. , M. T., Kretzler, M., Boucherot, A., Berra, S., Yasuda, Y., Henger, A., Eichinger, F., Gaiser, S., Schmid, H., Rastaldi, M. P., Schrier, R. W., Schlondorff, D., Cohen, C. D. (2007) Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J. Am. Soc. Nephrol. 18, 1765-1776.
<https://doi.org/10.1681/ASN.2006121304>
45. , F. G., Kuriki, P. S., Fujihara, C. K., Fanelli, C., Arias, S. C., Malheiros, D. M., Camara, N. O., Zatz, R. (2012) Chronic VEGF blockade worsens glomerular injury in the remnant kidney model. PLoS One 7, e39580.
<https://doi.org/10.1371/journal.pone.0039580>
46. , M. R., Davis, R., Norberg, S. M., O ́Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., Shalinsky, D. R., Hu-Lowe, D. D., McDonald, D. M. (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621.
<https://doi.org/10.1172/JCI24612>
47. , C., Sabbatini, R., Porta, C., Procopio, G., Di Lorenzo, G., Onofrio, A., Buti, S., Iacovelli, R., Invernizzi, R., Moscetti, L., Aste, M. G., Pagano, M., Grosso, F., Lucia Manenti, A., Ortega, C., Cosmai, L., Del Giovane, C., Conte, P. F. (2012) Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int. 110, 692-698.
<https://doi.org/10.1111/j.1464-410X.2012.10946.x>
48. , E. L., Dallabrida, S. M., Rupnick, M. A., Redline, W. M., Hannagan, K., Ismail, N. S., Burstein, H. J., Beckman, J. A. (2011) Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 58, 85-92.
<https://doi.org/10.1161/HYPERTENSIONAHA.110.168120>
49. , S. E., Min, J. Y., Merchan, J., Lim, K. H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., Epstein, F. H., Sukhatme, V. P., Karumanchi, S. A. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658.
<https://doi.org/10.1172/JCI17189>
50. , A. A., Murry, D. J., Owzar, K., Hollis, D. R., Kennedy, E. B., Abou-Alfa, G., Desai, A., Hwang, J., VillalonaCalero, M. A., Dees, E. C., Lewis, L. D., Fakih, M. G., Edelman, M. J., Millard, F., Frank, R. C., Hohl, R. J., Ratain, M. J. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27, 1800-1805.
<https://doi.org/10.1200/JCO.2008.20.0931>
51. , K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., Langmuir, V., Rugo, H. S. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792-799.
<https://doi.org/10.1200/JCO.2005.05.098>
52. , S., Fujino, M., Matsuo, Y., Tanigawa, H., Saku, K. (2005) Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens. Res. 28, 147-153.
<https://doi.org/10.1291/hypres.28.147>
53. , R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Sczylik, C., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M., Figlin, R. A. (2007) Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 125-134.
<https://doi.org/10.1056/NEJMoa065044>
54. , Y., Kume, H., Hosoda, C., Homma, Y. (2011) Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma. Case Report Med. 2011, 710216.
<https://doi.org/10.1155/2011/710216>
55. , J. J., Melville, V. P., Webb, D. J. (2006) Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 48, 622-627.
<https://doi.org/10.1161/01.HYP.0000239816.13007.c9>
56. , T. V., Morgan, J. A., Demetri, G. D., George, S., Maki, R. G., Quigley, M., Humphreys, B. D. (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J. Natl. Cancer Inst. 100, 282-284.
<https://doi.org/10.1093/jnci/djm311>
57. , D., Culine, S. (2008) High frequency of intracerebral haemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur. Urol. 53, 376-381.
<https://doi.org/10.1016/j.eururo.2007.08.053>
58. , A., Pavlik, T., Melichar, B., Puzanov, I., Dusek, L., Bortlicek, Z., Vyzula, R., Abrahamova, J., Buchler, T., on behalf of the Czech Renal Cancer Cooperative Group (2012) Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann. Oncol. 23, 3137-3143.
<https://doi.org/10.1093/annonc/mds145>
59. , P. M., Villavicencio, H. (2008) Sorafenib: tolerance in patients on chronic hemodialysis: a single center experience. Oncology 74, 245-246.
60. , B. F., Flyvbjerg, A., De Vriese, A. S. (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 65, 2003-2017.
<https://doi.org/10.1111/j.1523-1755.2004.00621.x>
61. , K., Eremina, V., Baelde, H., Min, W., Hirashima, M., Fantus, I. G., Quaggin, S. E. (2010) Glomerular structure and function require paracrine, not autocrine, VEGFVEGFR-2 signaling. J. Am. Soc. Nephrol. 21, 1691-1701.
<https://doi.org/10.1681/ASN.2010030295>
62. , H., Hamano,Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar, A., Kalluri, R. (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFLT-1) induces proteinuria. J. Biol. Chem. 278, 12605-12608.
<https://doi.org/10.1074/jbc.C300012200>
63. , S. B., Dallabrida, S. M., Durand, E., Ismail, N. S., Bazinet, L., Birsner, A. E., Sohn, R., Ikeda, S., Pu, W. T., Kulke, M. H., Javaherian, K., Zurakowski, D., Folkman, J. M., Rupnick, M. (2012) Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc. Natl. Acad. Sci. USA 109, 11306-11311.
<https://doi.org/10.1073/pnas.1203275109>
64. , D., Nagahama, K., Tsuura, Y., Tanaka, H., Tamura, T. (2012) Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin. Exp. Nephrol. 16, 310-315.
<https://doi.org/10.1007/s10157-011-0543-9>
65. , T,, Nangaku, M. (2010) The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 a in progression of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 19, 43-50.
<https://doi.org/10.1097/MNH.0b013e3283328eed>
66. , Y., Uemura, H., Fujimoto, H., Kanayama, H. O., Shinohara, N., Nakazawa, H., Imai, K., Umeyama, Y., Ozono, S., Naito, S., Akaza, H., Japan Axitinib Phase II Study Group (2011) Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur. J. Cancer 47, 2592-2602.
<https://doi.org/10.1016/j.ejca.2011.07.014>
67. , D., Reidy, K., Marlier, A., Bertuccio, C., Villegas, G., Jimenez, J., Kashgarian, M., Tufro, A. (2010a) Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid resistant nephrotic syndrome. Am. J. Pathol. 177, 2225-2233.
<https://doi.org/10.2353/ajpath.2010.091146>
68. , D., Reidy, K., Bertuccio, C., Teichman, J., Villegas, G., Jimenez, J., Shen, W., Kopp, J. B., Thomas, D. B., Tufro, A. (2010b) Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 77, 989-999.
<https://doi.org/10.1038/ki.2010.64>
69. , D., Bertuccio, C. A., Marlier, A, Reidy, K., Garcia, A. M., Jimenez, J., Velazquez, H., Kashgarian, M., Moeckel, G. W., Tufro, A. (2011) Podocyte vascular endothelial growth factor overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 54, 1227-1241.
<https://doi.org/10.1007/s00125-010-2034-z>
70. , D., Villegas, G., Aggarwal, P. K., Bertuccio, C., Jimenez, J., Velazquez, H., Reidy, K., Agrahamson, D. R., Moeckel, G., Kashgarian, M., Tufro, A. (2012) Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts ανβ3 integrin signaling in the glomerulus. PLoS One 7, e40589.
<https://doi.org/10.1371/journal.pone.0040589>
71. , C., Moeller, C. C., Altintas, M. M., Li, J., Schwarz, K., Zacchinga, S., Xie, L., Henger, A., Schmid, H., Rastaldi, M. P., Cowan, P., Kretzler, M., Parrilla, R., Bendayan, M., Gupta, V., Nikolic, B., Kalluri, R., Carmeliet, P., Mundel, P., Reiser, J. (2008) Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55-63.
<https://doi.org/10.1038/nm1696>
72. , C., El Hindi, S., Li, J., Fornoni, A., Goes, N., Sageshima, J., Maiguel, D., Karumanchi, S. A., Yap, H. K., Saleem, M., Zhang, Q., Nikolic, B., Chaudhuri, A., Daftarian, P., Salido, E., Torres, A., Salifu, M., Sarwal, M. M., Schaefer, F., Morath, C., Schwenger, V., Zeier, M., Gupta, V., Roth, D., Rastaldi, M. P., Burke, G., Ruiz, P., Reiser, J. (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960.
<https://doi.org/10.1038/nm.2411>
73. , S., Chen, J. J., Kudelka, A., Lu, J., Zhu, X. (2008) Incidence and risk of hypertension with sorafenib in patients with cancer; a systematic review and meta-analysis. Lancet Oncol. 9, 117-123.
<https://doi.org/10.1016/S1470-2045(08)70003-2>
74. , S., Kim, C., Baer, L, Zhu, X. (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J. Am. Soc. Nephrol. 21, 1381-1389.
<https://doi.org/10.1681/ASN.2010020167>
75. , J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., Rosenberg, S. A. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434.
<https://doi.org/10.1056/NEJMoa021491>
76. , J., Frieze, D., Martins, R., Carr, L. (2010) Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann. Pharmacother. 44, 1010-1015.
77. , X., Wu, S., Dahut, W. L., Parikh,C. R. (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49, 186-193.
<https://doi.org/10.1053/j.ajkd.2006.11.039>
78. , X., Stergiopoulos, K., Wu, S. (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhbitor sunitinib: systematic review and meta-analysis. Acta Oncol. 48, 9-17.
<https://doi.org/10.1080/02841860802314720>
